Quality of life in pregnant substance dependent women undergoing opioid maintenance therapy;Lebensqualitat gravider substanzabhangiger frauen unter oraler erhaltungstherapie mit synthetischen opioiden

Nervenheilkunde

Volumn 19, Issue 4, 2000, Pages 205-211

  Fischer, Gabriele ^a   Eder, H ^b   Peternell, Alexandra ^b   Windhaber, J ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

Maintenance therapy; Opioid dependence; Pregnancy; Quality of life

Indexed keywords

BUPRENORPHINE; METHADONE; MORPHINE; OPIATE; VENDAL;

ADULT; CLINICAL ARTICLE; ETHICS; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; METHADONE TREATMENT; OPIATE ADDICTION; PATIENT SATISFACTION; PREGNANCY COMPLICATION; QUALITY OF LIFE; REVIEW; WITHDRAWAL SYNDROME;

EID: 0034091528     PISSN: 07221541     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th Ed.(DSM-IV). Washington: American Psychiatric Association; 1994.
2. Blinick G, Jerez E, Wallach RC. Methadone maintenance, pregnancy and progeny. JAMA 1973; 225: 477-9.
3. Boer K, Smit BJ, van Huis AM, Hogerzeil HV. Substance use in pregnancy: do we care? Act Paed 1977; 404: 65-71.
4. Braucht GN, Reichardt CS, Geissler LJ, et al. Effective services for homeless substance abusers. J Addict Dis 1995; 14: 87-109.
5. Brockington IF, Kumar R. Motherhood and mentl illness, causes and consequences. London: Wright Press 1988.
6. Brown E, Zuckerman B. The infant of the drug abusing mother. Pediatr Ann 1991; 20: 555-63.
7. Bundesministerium für Arbeit, Gesundheit und Soziales, Republik Österreich. Suchtmittelgesetz 1998 (BGB1. I Nr. 112/1997), Anhang 1. Wien: Österr. Staatsdruckerei 1998.
8. Chasnoff IJ, Landress H, Barett M. The prevalence of illicit drug or alcohol use during pregnancy and discrepancies in mandatory reporting in Pinellas County, Florida. N Eng J Med 1990; 322: 1202-6.
9. DeLeon G, Jainchill N. Residential therapeutic communities for female substance abusers. Bull NY Academ Med 1991; 67: 277-90.
10. Doberczak TM, Kandall SR, Friedmann P. Relationships between maternal methadone dosage, maternal-neonatal methadone levels, and neonatal withdrawal. Obstet Gynecol 1993; 81: 936-40.
11. Dole VP, Nyswander M. A medical treatment for diacetylmorphine (heroin) addiction. JAMA 1965; 193: 80-4.
12. Emit-® Assay Troubleshooting Guide. Palo Alto: Syva Co 1983.
13. European Monitoring Center for Drugs and Drug Addiction. Annual report on the state of the drug problem in the European Union, European Communities. Lisboa 1996.
14. Fagerström KO. Measuring degree of physical dependence to tobacco smoking with reference to individualisation of treatment. Addict Behav 1978; 3: 235-41.
15. Finnegan LP. Treatment during the perinatal period. J Psychoact Drugs 1991; 23 (2): 191-201.
16. Finnegan LP. Clinical effects of pharmacologic agents on pregnancy and the neonate. Ann NY Acad Sci 1976; 281: 74-89.
17. Fischer G, Eder H, Jagsch R, Lenkh C, Habeler A, Aschauer HN, Kasper S. Maintenance therapy with synthetic opioids within a multidisciplinary program - A stabilizing necessity for pregnant opioid dependent women. Arch Wom Ment Health 1998; 1: 109-16.
18. Fischer G, Etzersdorfer P, Eder H, Jagsch R, Langer M, Weninger M. Buprenorphine maintenance in pregnant opiate addicts. Europ Add Res 1998; 4 (Suppl. 1): 32-6.
19. Fischer G, Jagsch R, Eder H, Gombas W, Etzersdorfer P, Schmidl-Mohl K, et al. Comparison of methadone and slow-release morphine maintenance in pregnant addicts. Addiction 1999; 94 (2): 231-9.
20. Franques P, Auriacombe M, Grabot D, Tignol J. Quality of life in methadone and buprenorphine maintenance treatments. Abstract at the CPDD 1997 Annual Meeting, Nashville 1997, Abstractbook p. 47.
21. Giles W, Patterson T, Sanders RN, Batey R, Thomas D, Collins J. Outpatient methadone program for pregnant heroin using woman. Aust N Z J Obstet Gynaecol 1989; 29: 225-9.
22. Holcomb WR, Parker JC, Leong GB. Outcomes of inpatients treatment on a VA psychiatric unit and a substance abuse treatment unit. Psychiatric Services 1997; 48: 699-704.
23. Jarvis MAE, Schnoll SH. Methadone Use During Pregnancy. NIDA Res Monogr 1995; 149: 58-77.
24. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA 1992; 267: 2750-5.
25. Kaltenbach K, Finnegan LP. Neonatal abstinence syndrome, pharmacotherapy and developmental outcome. Neurobehav Toxicol Teratol 1986; 8: 353-5.
26. Kandall SR, Doberczak TM, Mauer KR, Strashun RH, Korts DC. Opiate vs CNS depressant therapy in neonatal drug abstinence syndrome. Am J Dis Child 1983; 137: 378-82.
27. Katschnig H. How useful is the concept of quality of life in psychiatry? In: Katschnig H, Freeman H, Sartorius N (Eds). Quality of Life in Mental Disorders. Chichester: John Wiley & Sons 1997.
28. Leshner AI: Addiction is a brain disease, and it matters. Science 1997; 278: 45-7.
29. Lewis JW, Rance MJ, Sanger DJ. The pharmacology and abuse potential of buprenorphine: a new antagonistic analgesic. Adv Subst Abuse 1983; 3: 103-54.
30. Marquet P, Chevrel J, Lavignasse P, Merle L, Lachatre G. Buprenorphine withdrawal syndrome in a newborn. Clin Pharm Ther 1977; 62 (5): 569-71.
31. McLellan A, Kushner H, Metzger D, Peters R, Smith I, Grissom G, et al. Addiction severity index. 5th edn. J Subst Abuse Treat 1992; 9: 199-213.
32. Nadelmann E, McNeely J, Drucker E. International perspectives. In: Lowinson JH, Ruiz P, Millmann RB, Langrod JG, editors. Substance abuse. A comprehensive textbook, 3rd edition. Baltimore: Williams & Wilkins 1997; 23-39.
33. Nieburg P, Marks JS, McLaren NM, Remington PL. The fetal tobacco syndrome. JAMA 1985; 253: 2998-9.
34. Oliver JPJ. The social care directive: development of a quality of life profile for use in community services for the mentally ill. Social Work and Social Science Review 1991; 3: 5-45.
35. Priebe S, Hoffmann C: Berliner Lebensqualitätsprofil. Manuskript 1993.
36. Reed BG. Developing women-sensitive drug dependence treatment services: Why so difficult? J Psychoact Drugs 1987; 19: 151-64.
37. Root MPP. Treatment failures: The role of sexual victimization in womens addictive behaviour. Am J Orthopsych 1989; 59: 542-9.
38. Shaw NJ, McIvor L. Neonatal abstinence syndrome after maternal methadone treatment. Arch Dis Child 1994; 71: F203-5.
39. Smit DW. The Fetal Alcohol Syndrom. Hosp Pract 1979; 14: 121.
40. Streissguth AP, Barr H, Sampson PD, Bookstein FL. Prenatal alcohol and offspring developement: the first 14 years. Drug Alc Dep 1994; 36: 89-99.
41. Torrens M, San L, Martinez A, Castillo C, Domingo-Salvany A, Alonso J. Use of the Nottingham Health Profile for measuring health status of patients in methadone maintenance treatment. Addiction 1997; 92: 707-16.
42. US Department of Health and Human Services. The health consequences of smoking for women: A report of the Surgeon General. Washington DC 1980.